Last reviewed · How we verify
intravenous use of sulodexide followed by oral use — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
intravenous use of sulodexide followed by oral use (intravenous use of sulodexide followed by oral use) — Sun Yat-sen University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| intravenous use of sulodexide followed by oral use TARGET | intravenous use of sulodexide followed by oral use | Sun Yat-sen University | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- intravenous use of sulodexide followed by oral use CI watch — RSS
- intravenous use of sulodexide followed by oral use CI watch — Atom
- intravenous use of sulodexide followed by oral use CI watch — JSON
- intravenous use of sulodexide followed by oral use alone — RSS
Cite this brief
Drug Landscape (2026). intravenous use of sulodexide followed by oral use — Competitive Intelligence Brief. https://druglandscape.com/ci/intravenous-use-of-sulodexide-followed-by-oral-use. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab